187 related articles for article (PubMed ID: 37893133)
1. MicroRNAs Associated with Disability Progression and Clinical Activity in Multiple Sclerosis Patients Treated with Glatiramer Acetate.
Casanova I; Domínguez-Mozo MI; De Torres L; Aladro-Benito Y; García-Martínez Á; Gómez P; Abellán S; De Antonio E; Álvarez-Lafuente R
Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893133
[TBL] [Abstract][Full Text] [Related]
2. microRNA Expression and Its Association With Disability and Brain Atrophy in Multiple Sclerosis Patients Treated With Glatiramer Acetate.
Dominguez-Mozo MI; Casanova I; De Torres L; Aladro-Benito Y; Perez-Perez S; Garcia-Martínez A; Gomez P; Abellan S; De Antonio E; Lopez-De-Silanes C; Alvarez-Lafuente R
Front Immunol; 2022; 13():904683. PubMed ID: 35774792
[TBL] [Abstract][Full Text] [Related]
3. miRNA 548a-3p as biomarker of NEDA-3 at 2 years in multiple sclerosis patients treated with fingolimod.
Gonzalez-Martinez A; Patel R; Healy BC; Lokhande H; Paul A; Saxena S; Polgar-Turcsanyi M; Weiner HL; Chitnis T
J Neuroinflammation; 2023 May; 20(1):131. PubMed ID: 37254147
[TBL] [Abstract][Full Text] [Related]
4. miR-132-3p, miR-106b-5p, and miR-19b-3p Are Associated with Brain-Derived Neurotrophic Factor Production and Clinical Activity in Multiple Sclerosis: A Pilot Study.
Sağır F; Ersoy Tunalı N; Tombul T; Koral G; Çırak S; Yılmaz V; Türkoğlu R; Tüzün E
Genet Test Mol Biomarkers; 2021 Nov; 25(11):720-726. PubMed ID: 34788141
[No Abstract] [Full Text] [Related]
5. Temporal variability of serum miR-191, miR-223, miR-128, and miR-24 in multiple sclerosis: A 4-year follow-up study.
Vistbakka J; Sumelahti ML; Lehtimäki T; Hagman S
J Neurol Sci; 2022 Nov; 442():120395. PubMed ID: 36084364
[TBL] [Abstract][Full Text] [Related]
6. Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis.
Waschbisch A; Atiya M; Linker RA; Potapov S; Schwab S; Derfuss T
PLoS One; 2011; 6(9):e24604. PubMed ID: 21949733
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of serum miR-191-5p, miR-24-3p, miR-128-3p, and miR-376c-3 in multiple sclerosis patients.
Vistbakka J; Sumelahti ML; Lehtimäki T; Elovaara I; Hagman S
Acta Neurol Scand; 2018 Aug; 138(2):130-136. PubMed ID: 29527713
[TBL] [Abstract][Full Text] [Related]
8. Multiplex Analysis of Cerebrospinal Fluid and Serum Exosomes MicroRNAs of Untreated Relapsing Remitting Multiple Sclerosis (RRMS) and Proposing Noninvasive Diagnostic Biomarkers.
Mohammadinasr M; Montazersaheb S; Molavi O; Kahroba H; Talebi M; Ayromlou H; Hejazi MS
Neuromolecular Med; 2023 Sep; 25(3):402-414. PubMed ID: 37020076
[TBL] [Abstract][Full Text] [Related]
9. Potential prognostic value of circulating inflamma-miR-146a-5p and miR-125a-5p in relapsing-remitting multiple sclerosis.
Giuliani A; Lattanzi S; Ramini D; Graciotti L; Danni MC; Procopio AD; Silvestrini M; Olivieri F; Sabbatinelli J
Mult Scler Relat Disord; 2021 Sep; 54():103126. PubMed ID: 34243103
[TBL] [Abstract][Full Text] [Related]
10. Early miR-320b and miR-25-3p miRNA levels correlate with multiple sclerosis severity at 10 years: a cohort study.
Gonzalez-Martinez A; Bose G; Lokhande H; Saxena S; Healy BC; Polgar-Turcsanyi M; Weiner HL; Chitnis T
J Neuroinflammation; 2023 Jun; 20(1):136. PubMed ID: 37264432
[TBL] [Abstract][Full Text] [Related]
11. Identification of MS-specific serum miRNAs in an international multicenter study.
Regev K; Healy BC; Paul A; Diaz-Cruz C; Mazzola MA; Raheja R; Glanz BI; Kivisäkk P; Chitnis T; Jagodic M; Piehl F; Olsson T; Khademi M; Hauser S; Oksenberg J; Khoury SJ; Weiner HL; Gandhi R
Neurol Neuroimmunol Neuroinflamm; 2018 Sep; 5(5):e491. PubMed ID: 30175165
[TBL] [Abstract][Full Text] [Related]
12. Exosomal microRNA signatures in multiple sclerosis reflect disease status.
Ebrahimkhani S; Vafaee F; Young PE; Hur SSJ; Hawke S; Devenney E; Beadnall H; Barnett MH; Suter CM; Buckland ME
Sci Rep; 2017 Oct; 7(1):14293. PubMed ID: 29084979
[TBL] [Abstract][Full Text] [Related]
13. Erythrocyte microRNA sequencing reveals differential expression in relapsing-remitting multiple sclerosis.
Groen K; Maltby VE; Lea RA; Sanders KA; Fink JL; Scott RJ; Tajouri L; Lechner-Scott J
BMC Med Genomics; 2018 May; 11(1):48. PubMed ID: 29783973
[TBL] [Abstract][Full Text] [Related]
14. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
15. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM
J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877
[TBL] [Abstract][Full Text] [Related]
16. Association Between Serum MicroRNAs and Magnetic Resonance Imaging Measures of Multiple Sclerosis Severity.
Regev K; Healy BC; Khalid F; Paul A; Chu R; Tauhid S; Tummala S; Diaz-Cruz C; Raheja R; Mazzola MA; von Glehn F; Kivisakk P; Dupuy SL; Kim G; Chitnis T; Weiner HL; Gandhi R; Bakshi R
JAMA Neurol; 2017 Mar; 74(3):275-285. PubMed ID: 28114622
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
Cochrane Database Syst Rev; 2013 Jun; (6):CD008933. PubMed ID: 23744561
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of miR-125a-5p and miR-218-5p in Peripheral Blood Mononuclear Cells of Patients with Relapsing-Remitting Multiple Sclerosis.
Mosarrezaii Aghdam A; Rezaei S; Zarza Nalivan F; Babaie F; Amiri Nikpour MR; Torkamandi S
Immunol Invest; 2022 Jul; 51(5):1149-1161. PubMed ID: 33866949
[TBL] [Abstract][Full Text] [Related]
19. Upregulated serum miR-128-3p in progressive and relapse-free multiple sclerosis patients.
Zanoni M; Orlandi E; Rossetti G; Turatti M; Calabrese M; Gomez Lira M; Gajofatto A
Acta Neurol Scand; 2020 Nov; 142(5):511-516. PubMed ID: 32432792
[TBL] [Abstract][Full Text] [Related]
20. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
